Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy.

被引：0
|
作者：
Shi, Wenting [1 ]
Tang, Xuzhen [2 ]
Zhang, Jingying [1 ]
Kuang, Xinhong [1 ]
Zhang, Yan [1 ]
Wang, Jingjing [1 ]
Gu, Qingyang [1 ]
Ji, Qunsheng [2 ]
机构：
[1] WuXi AppTec Suzhou Co Ltd, Suzhou, Peoples R China
[2] WuXi AppTec Shanghai Co Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3004
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [2] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [3] Development of Patient-Derived Colorectal Cancer Xenograft and Organoid Models with Acquired Resistance to KRAS G12C Inhibitors
    Hua, L.
    Zheng, J.
    Wang, J.
    Shang, L.
    Qian, W.
    Sun, Y.
    Bourre, L.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S104 - S105
  • [4] Clinical Data for KRAS G12C Inhibitors
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
  • [5] Targeting FAK to improve the therapy of KRAS G12C mutant cancers
    Liu, Shuang
    Shi, Junfen
    Lu, Chang
    Zhang, Miao
    Xin, Ying
    Zhu, Yan
    Li, Jijun
    Luo, Hong
    Sun, Yinghui
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [7] Small Molecule Imaging Agent for Mutant KRAS G12C
    Koch, Peter D.
    Quintana, Jeremy
    Ahmed, Maaz S.
    Kohler, Rainer H.
    Weissleder, Ralph
    ADVANCED THERAPEUTICS, 2021, 4 (05)
  • [8] G12C KRAS mutant colorectal cancer, optimising the target
    Price, T. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1300 - S1300
  • [9] Establishment of KRAS G12C mutated colorectal cancer cells and drug screening for the combination therapy.
    Maruyama, Kohei
    Shimizu, Yuki
    Oh-hara, Tomoko
    Nagayama, Satoshi
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2021, 112 : 799 - 799
  • [10] KRAS G12C mutation is not undruggable anymore
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
12345